Anna-Barbara Moscicki1, Teresa M Darragh, J Michael Berry-Lawhorn, Jennifer M Roberts, Michelle J Khan, Lori A Boardman, Elizabeth Chiao, Mark H Einstein, Stephen E Goldstone, Naomi Jay, Wendy M Likes, Elizabeth A Stier, Mark L Welton, Dorothy J Wiley, Joel M Palefsky. 1. 1Division of Adolescent and Young Adult Medicine, Department of Pediatrics, University of California, San Francisco, CA, USA; 2Department of Clinical Pathology, University of California, San Francisco, CA, USA; 3Division of Hematology Oncology, University of California San Francisco, CA, USA; 4Douglass Hanly Moir Pathology, Sydney, Australia; 5Division of Women's Reproductive Healthcare, Department of OB/GYN, School of Medicine, University of Alabama at Birmingham, AL, USA; 6Florida Hospital for Women, Florida Hospital System, University of Central Florida College of Medicine, FL, USA; 7Center for Innovations in Quality, Effectiveness, and Safety, Michael E. DeBakey VA Medical Center, Houston, TX, USA; 8Department of Obstetrics and Gynecology & Women's Health, Albert Einstein College of Medicine, Montefiore Medical Center, New York, NY; 9Icahn School of Medicine at Mount Sinai, New York, NY, USA; 10Anal Neoplasia Clinic, Research and Education (ANCRE) Center, University of California, San Francisco, CA, USA; 11College of Medicine, Department of Obstetrics and Gynecology, University of Tennessee Health Science Center, Memphis, TN, USA; 12Obstetrics and Gynecology, Boston Medical Center, Boston, MA, USA; 13Colon and Rectal Surgery, Stanford University School of Medicine, Stanford Hospital and Clinics, Stanford, CA, USA; 14School of Nursing, University of California, Los Angeles, CA, USA; 15Department of Infectious Diseases, University of California, San Francisco, CA, USA.
Abstract
OBJECTIVE: The incidence of anal cancer is higher in women than men in the general population and has been increasing for several decades. Similar to cervical cancer, most anal cancers are associated with human papillomavirus (HPV), and it is believed that anal cancers are preceded by anal high-grade squamous intraepithelial lesions (HSIL). Our goals were to summarize the literature on anal cancer, HSIL, and HPV infection in women and to provide screening recommendations in women. METHODS: A group of experts convened by the American Society for Colposcopy and Cervical Pathology and the International Anal Neoplasia Society reviewed the literature on anal HPV infection, anal SIL, and anal cancer in women. RESULTS: Anal HPV infection is common in women but is relatively transient in most. The risk of anal HSIL and cancer varies considerably by risk group, with human immunodeficiency virus-infected women and those with a history of lower genital tract neoplasia at highest risk compared with the general population. CONCLUSIONS: While there are no data yet to demonstrate that identification and treatment of anal HSIL leads to reduced risk of anal cancer, women in groups at the highest risk should be queried for anal cancer symptoms and required to have digital anorectal examinations to detect anal cancers. Human immunodeficiency virus-infected women and women with lower genital tract neoplasia may be considered for screening with anal cytology with triage to treatment if HSIL is diagnosed. Healthy women with no known risk factors or anal cancer symptoms do not need to be routinely screened for anal cancer or anal HSIL.
OBJECTIVE: The incidence of anal cancer is higher in women than men in the general population and has been increasing for several decades. Similar to cervical cancer, most anal cancers are associated with human papillomavirus (HPV), and it is believed that anal cancers are preceded by anal high-grade squamous intraepithelial lesions (HSIL). Our goals were to summarize the literature on anal cancer, HSIL, and HPV infection in women and to provide screening recommendations in women. METHODS: A group of experts convened by the American Society for Colposcopy and Cervical Pathology and the International Anal Neoplasia Society reviewed the literature on anal HPV infection, anal SIL, and anal cancer in women. RESULTS:Anal HPV infection is common in women but is relatively transient in most. The risk of anal HSIL and cancer varies considerably by risk group, with humanimmunodeficiency virus-infectedwomen and those with a history of lower genital tract neoplasia at highest risk compared with the general population. CONCLUSIONS: While there are no data yet to demonstrate that identification and treatment of anal HSIL leads to reduced risk of anal cancer, women in groups at the highest risk should be queried for anal cancer symptoms and required to have digital anorectal examinations to detect anal cancers. Humanimmunodeficiency virus-infectedwomen and women with lower genital tract neoplasia may be considered for screening with anal cytology with triage to treatment if HSIL is diagnosed. Healthy women with no known risk factors or anal cancer symptoms do not need to be routinely screened for anal cancer or anal HSIL.
Authors: Mark Gilbert; Michael Kwag; Wendy Mei; Claudia Rank; Rhonda Kropp; Alberto Severini; Dirk van Niekerk; Chen Zhou; Natasha Press; Gina Ogilvie; Tom Wong Journal: Sex Transm Dis Date: 2011-10 Impact factor: 2.830
Authors: Amanda J Durante; Ann B Williams; Maria Da Costa; Teresa M Darragh; Kaveh Khoshnood; Joel M Palefsky Journal: Cancer Epidemiol Biomarkers Prev Date: 2003-07 Impact factor: 4.254
Authors: Ricard Cervera; Munther A Khamashta; Josep Font; Gian Domenico Sebastiani; Antonio Gil; Paz Lavilla; Juan Carlos Mejía; A Olcay Aydintug; Hanna Chwalinska-Sadowska; Enrique de Ramón; Antonio Fernández-Nebro; Mauro Galeazzi; Merete Valen; Alessandro Mathieu; Frédéric Houssiau; Natividad Caro; Paula Alba; Manuel Ramos-Casals; Miguel Ingelmo; Graham R V Hughes Journal: Medicine (Baltimore) Date: 2003-09 Impact factor: 1.889
Authors: Cecile D Lahiri; Minh Ly Nguyen; C Christina Mehta; Marina Mosunjac; Talaat Tadros; Elizabeth R Unger; Mangalathu S Rajeevan; Jendai Richards; Ighovwerha Ofotokun; Lisa Flowers Journal: Clin Infect Dis Date: 2020-03-03 Impact factor: 9.079
Authors: Ashish A Deshmukh; Ryan Suk; Meredith S Shiels; Kalyani Sonawane; Alan G Nyitray; Yuxin Liu; Michael M Gaisa; Joel M Palefsky; Keith Sigel Journal: J Natl Cancer Inst Date: 2020-08-01 Impact factor: 13.506
Authors: Yuxin Liu; Morgan Blakely; Keith Sigel; Tin Htwe Thin; Pei Hui; Michael Donovan; Michael M Gaisa Journal: AIDS Date: 2018-10-23 Impact factor: 4.177